Products Categories
    Product Certification&
    Enterprise Certification

  • Mr.zhang wenfa
    Tel: +86-556-5800026

  • Ms.Olivia Liu
    Tel: 086-556-5800080

  • Mobile:+86-18133004126
  • Tel:+86-556-5800026
  • Fax:+86-556-5800026
  • Province/state:Anhui
  • City:Anqing
  • Street:Daguan Economic Development Zone of circular economy industrial park Anqing City Anhui province
  • MaxCard:
Home > Products >  Sovaldi GS-7977 API PSI7977 sofosbuvir 1190307-88-0 competitive price manufacturer producer factory in China

Sovaldi GS-7977 API PSI7977 sofosbuvir 1190307-88-0 competitive price manufacturer producer factory in China CAS NO.1190307-88-0

  • FOB Price: USD: 170.00-170.00 /Gram Get Latest Price
  • Min.Order: 1 Gram
  • Payment Terms: L/C,T/T
  • Available Specifications:

    1(1-10)Gram

  • Product Details

Keywords

  • sofosbuvir
  • 1190307-88-0
  • API

Quick Details

  • ProName: Sovaldi GS-7977 API PSI7977 sofosbuvi...
  • CasNo: 1190307-88-0
  • Molecular Formula: C22H29FN3O9P
  • Appearance: White powder
  • Application: 1190307-88-0
  • Port: Shanghai
  • ProductionCapacity: 10 Metric Ton/Month
  • Purity: 99
  • LimitNum: 1 Gram

Superiority

  • ProName: Sofosbuvir/CAS:1190307-88-0
  • CasNo: 1190307-88-0
  • Appearance: White powder
  • Application: 1190307-88-0
  • DeliveryTime: ASAP after payment
  • PackAge: AS required
  • Port: any port in China
  • ProductionCapacity: Metric Ton/Day
  • Purity: 99%
  • Storage: room temperature
  • Transportation: by sea or by air
  • LimitNum: 1 Gram

Details

Sofosbuvir is used for the treatment of chronic hepatitis C, genotypes 1, 2, 3 and 4, in combination with pegylated interferon and ribavirin, or with ribavirin alone. It is also used in HCV patients with an HIV coinfection.[8] The treatment is based on a number of clinical trials, for example the ELECTRON trial which showed that a dual interferon-free regimen of sofosbuvir plus ribavirin produced a 24-week post-treatment sustained virological response (SVR24) rate of 100% for previously untreated patients with HCV genotypes 2 or 3.[14][15]

In early 2014, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) jointly published a recommendation for the management of hepatitis C. In this recommendation, sofosbuvir and ribavirin, with or without pegylated interferon, are part of all first-line treatments for HCV genotypes 1 to 6, and are also part of some second-line treatments.

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog